1. Home
  2. OSRH vs LEXX Comparison

OSRH vs LEXX Comparison

Compare OSRH & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.40

Market Cap

18.4M

Sector

N/A

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.69

Market Cap

16.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSRH
LEXX
Founded
N/A
2004
Country
United States
Canada
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
16.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OSRH
LEXX
Price
$0.40
$0.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
433.1K
156.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.46
52 Week High
$4.33
$1.90

Technical Indicators

Market Signals
Indicator
OSRH
LEXX
Relative Strength Index (RSI) 35.07 50.73
Support Level $0.39 $0.46
Resistance Level $0.76 $0.83
Average True Range (ATR) 0.04 0.06
MACD -0.00 0.01
Stochastic Oscillator 12.21 80.84

Price Performance

Historical Comparison
OSRH
LEXX

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: